Voyager Therapeutics Inc (VYGR) Receives Average Rating of “Buy” from Analysts

Shares of Voyager Therapeutics Inc (NASDAQ:VYGR) have received an average rating of “Buy” from the thirteen research firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $32.14.

Several analysts have recently issued reports on the stock. BTIG Research reissued a “buy” rating and issued a $32.00 price target on shares of Voyager Therapeutics in a research report on Monday, September 10th. Morgan Stanley reissued an “equal weight” rating and issued a $27.00 price target on shares of Voyager Therapeutics in a research report on Monday, September 10th. Chardan Capital reissued a “hold” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday, June 21st. ValuEngine raised shares of Voyager Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. Finally, Zacks Investment Research raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 11th.

In other news, Director James A. Geraghty bought 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The shares were acquired at an average price of $19.39 per share, with a total value of $58,170.00. Following the acquisition, the director now owns 76,588 shares of the company’s stock, valued at approximately $1,485,041.32. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Glenn Pierce bought 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 12th. The shares were purchased at an average cost of $18.44 per share, for a total transaction of $92,200.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 11,000 shares of company stock worth $205,300 in the last ninety days. 33.60% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of the stock. Northern Trust Corp grew its stake in Voyager Therapeutics by 33.5% in the 2nd quarter. Northern Trust Corp now owns 267,441 shares of the company’s stock worth $5,226,000 after buying an additional 67,063 shares in the last quarter. Trustees of Princeton University purchased a new position in Voyager Therapeutics in the 2nd quarter worth approximately $3,979,000. MetLife Investment Advisors LLC grew its stake in Voyager Therapeutics by 38.6% in the 2nd quarter. MetLife Investment Advisors LLC now owns 10,649 shares of the company’s stock worth $208,000 after buying an additional 2,964 shares in the last quarter. Metropolitan Life Insurance Co. NY grew its stake in Voyager Therapeutics by 53.6% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock worth $177,000 after buying an additional 3,157 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Voyager Therapeutics by 207.7% in the 2nd quarter. Bank of America Corp DE now owns 26,046 shares of the company’s stock worth $509,000 after buying an additional 17,580 shares in the last quarter. 89.64% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ VYGR traded down $0.86 during midday trading on Thursday, hitting $15.15. The company’s stock had a trading volume of 332,800 shares, compared to its average volume of 410,860. Voyager Therapeutics has a one year low of $11.54 and a one year high of $31.91. The firm has a market cap of $613.69 million, a P/E ratio of -5.77 and a beta of 2.94.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.13). Voyager Therapeutics had a negative net margin of 731.88% and a negative return on equity of 80.68%. The business had revenue of $2.58 million during the quarter, compared to the consensus estimate of $3.00 million. As a group, equities research analysts expect that Voyager Therapeutics will post -3.12 earnings per share for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

See Also: Why is insider trading harmful?

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply